Latest On Leap Therapeutics, Inc (LPTX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 12:07 EST | News | Leap Therapeutics GAAP EPS of -$0.32 misses by $0.23 | N/A |  |
| 2023-03-24 12:58 EST | News | Leap Therapeutics GAAP EPS of -$0.11 in-line | N/A | |
| 2023-01-19 20:31 EST | News | Leap rebounds as Astellas posts Phase 3 data for rival cancer candidate | N/A | |
| 2023-01-17 09:37 EST | News | Leap Therapeutics falls after all-stock deal to acquire Flame Biosciences | N/A | |
| 2022-11-16 14:24 EST | News | Leap Therapeutics,(LPTX) Investor Presentation - Slideshow | N/A | |
About Leap Therapeutics, Inc (LPTX):
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
General
- Name Leap Therapeutics, Inc
- Symbol LPTX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 30
- Fiscal Year EndDecember
- IPO Date2017-01-25
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.leaptx.com
Valuation
- Price/Sales (Trailing 12 Mt.) 93.66
- Price/Book (Most Recent Quarter) 2.56
- Enterprise Value Revenue 69.95
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.46
- Next Year EPS Estimate -$0.57
- Next Quarter EPS Estimate -$0.10
- Operating Margin -1887%
- Return on Assets -57%
- Return on Equity -123%
- Revenue 1.5 million
- Earnings Per Share -$1.66
- Revenue Per Share $0.03
- Gross Profit 1.5 million
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 148.55 million
- EBITDA -34773000
- PEG Ratio 0.75
- Analyst Target Price $5.3
- Book Value Per Share $0.78
Share Statistics
- Shares Outstanding 59.66 million
- Shares Float 37.28 million
- % Held by Insiders 1204%
- % Held by Institutions 59.02%
- Shares Short 1.22 million
- Shares Short Prior Month 1.06 million
- Short Ratio 1.24
- Short % of Float 3%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.34
- 52 Week High $3.24
- 52 Week Low $1.2
- 50 Day Moving Average 2.48
- 200 Day Moving Average 2.1
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Leap Therapeutics, Inc (LPTX) Dividend Calendar:
Leap Therapeutics, Inc (LPTX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Leap Therapeutics, Inc (LPTX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Leap Therapeutics, Inc (LPTX) Chart:
Leap Therapeutics, Inc (LPTX) News:
Below you will find a list of latest news for Leap Therapeutics, Inc (LPTX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Leap Therapeutics, Inc (LPTX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest LPTX Trades:
Leap Therapeutics, Inc (LPTX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-16 | EFFECT (Notice of Effectiveness) | |
| 2020-10-14 | S-3/A (Registration statement under Securities Act of 1933) | |
| 2020-09-24 | 8-K (Current report) | |
| 2020-09-21 | 8-K (Current report) | |
| 2020-09-14 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-09-10 | 8-K (Current report) | |
| 2020-08-21 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-25 | 8-K (Current report) | |
Leap Therapeutics, Inc (LPTX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Leap Therapeutics, Inc (LPTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1204%
Institutional Ownership: 5902%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-22 | PERCEPTIVE ADVISORS LLC | 10% Share Holder | Buy | 1,750,000.00 | 2.00 | 3,500,000.00 | 8,476,496.00 | |
| 2019-02-05 | AUGUSTINE LAWLOR | Chief Operating Officer | Buy | 571,428.00 | 1.75 | 999,999.00 | 4,114,804.00 | |
| 2019-02-05 | Christopher Mirabelli | CEO, President, Chairman | Buy | 571,428.00 | 1.75 | 999,999.00 | 4,114,804.00 | |
| 2019-02-05 | DOUGLAS E ONSI | CFO, GC, Treasurer & Secretary | Buy | 571,428.00 | 1.75 | 999,999.00 | 4,114,804.00 | |
| 2019-02-05 | HealthCare Ventures IX, L.P. | 10% Share Holder | Buy | 571,428.00 | 1.75 | 999,999.00 | 4,144,804.00 | |